RE:RE:MYM NeutraceuticalsThe Laval Facility – phase one of the Laval facility is 10,000 sf. Phase two, scheduled to be completed in 2018, will see the growing area expanded to 37,000 sf. This license will enable MYM to manufacture its branded medicinal THC and CBD products. The Laval project is estimated to produce gross sales of $27 million by 2019 with profit estimates of $17 million, based on current per gram prices of $8.50.
Read more at https://www.stockhouse.com/news/press-releases/2017/12/15/mym-submits-confirmation-of-readiness-for-a-license-under-the-acmpr-to-health#5MWyuBc9jt8zi407.99